SML3100
AFMT racemate
≥98% (HPLC), E. faecalis pyridoxal-5′-phosphate-dependent tyrosine decarboxylase inhibitor, powder
别名:
α-(Fluoromethyl)-D/L-tyrosine, (R/S)-α-Fluoromethyltyrosine, (R/S)-2-Amino-3-fluoro-2-(4-hydroxybenzyl)propanoic acid, Alpha-(FluoroMethyl)-D/L-Tyrosine, D/L-AFMT
产品名称
AFMT racemate, ≥98% (HPLC)
InChI
1S/C10H12FNO3/c11-6-10(12,9(14)15)5-7-1-3-8(13)4-2-7/h1-4,13H,5-6,12H2,(H,14,15)
InChI key
ACIQAJKTARSFHQ-UHFFFAOYSA-N
SMILES string
OC1=CC=C(C=C1)CC(N)(C(O)=O)CF
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
A racemic mixture of D- and L-AFMT. L-AFMT is reported to selectively inhibt against gut bacteria E. faecalis pyridoxal-5′-phosphate (PLP)-dependent tyrosine decarboxylase (TyrDC)-, but not aromatic amino acid decarboxylase (AADC)-, mediated L-dopa decarboxylation (IC50 = 4.7 μM/cell-free, 1.4 μM/in E. faecalis cultures; 20% human AADC inhibition at 650 μM) via covalent adduct formation with TyrDC co-factor PLP. When co-administered with L-dopa (10 mg/kg) and the AADC inhibitor carbidopa (30 mg/kg) to gnotobiotic mice colonized with E. faecalis, L-AFMT (25 mg/kg) significantly increases L-dopa peak serum concentration.
Covalent inhibtor against L-dopa decarboxylation by gut bacteria E. faecalis tyrosine decarboxylase (TyrDC), but not aromatic amino acid decarboxylase (AADC).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Vayu Maini Rekdal et al.
Science (New York, N.Y.), 364(6445) (2019-06-15)
The human gut microbiota metabolizes the Parkinson's disease medication Levodopa (l-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted drugs are
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持